



KAREN L. SMITH, MD, MPH
Director & State Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

Office of AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2019-15

DATE: June 17, 2019

TO: ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF TENOFOVIR ALAFENAMIDE (VEMLIDY®)

Effective May 24, 2019, tenofovir alafenamide (Vemlidy®) have been added to the ADAP formulary. Tenofovir alafenamide is an ingredient found in antiretroviral combination drugs already on the ADAP formulary but on November 10, 2016, the U.S. Food and Drug Administration approved Vemlidy® as a stand alone medication for treatment of chronic HBV in adults with compensated liver disease. The addition of Vemlidy® to the ADAP formulary would provide prescribers with another treatment option to improve the overall health of their HIV/HBV co-infected clients. The ADAP MAC members voted to recommend the addition of Vemlidy® to the ADAP formulary with clinical restrictions to ensure appropriate dispensing.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The [ADAP drug formulary](#) has been updated to reflect the addition of Vemlidy®. Access the updated formulary at the following URL: <https://cdph.magellanrx.com/member/documents>.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,

A handwritten signature in blue ink, appearing to read "Sandra Robinson", with a long horizontal flourish extending to the right.

Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health